-
SR-202: Selective PPARĪ³ Antagonist for Immunometabolic Re...
2025-10-22
SR-202 (PPAR antagonist) enables precise dissection of the PPAR signaling pathway, offering unique advantages for insulin resistance, obesity, and immunometabolic disease research. Its selective nuclear receptor inhibition empowers advanced protocols in adipocyte differentiation, macrophage polarization, and translational drug development.
-
TAK-242: Advancing TLR4 Inhibition for Translational Immu...
2025-10-21
Explore TAK-242, a selective TLR4 inhibitor, as a transformative tool for dissecting innate-adaptive immune crosstalk, translational immunology, and neuropsychiatric disorder models. This article delivers an advanced, application-focused analysis unavailable elsewhere.